Literature DB >> 21690175

The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics.

Krista A Payne1, Sepideh F Varon, Ariane K Kawata, Karen Yeomans, Teresa K Wilcox, Aubrey Manack, Dawn C Buse, Richard B Lipton, Peter J Goadsby, Andrew M Blumenfeld.   

Abstract

OBJECTIVE: To describe a survey methodology to evaluate headache characteristics and burden and to present baseline characteristics for the international cohort of survey participants.
METHODS: A targeted, web-based methodology was used to recruit and survey subjects with migraine in 10 countries. Based on reported symptoms, subjects meeting ICHD-2 criteria for migraine were included; eligible subjects were classified as chronic (≥ 15 headache days per month) or episodic (< 15 headache days per month). Outcomes included sociodemographic and clinical characteristics, resource utilization, disability, health-related quality of life, anxiety, depression and productivity.
RESULTS: Of 23,312 survey respondents, 11,897 were eligible and 9715 (81.7%) completed the survey; subjects were 81.5% female; 5.7% (n = 555) had chronic migraine.
CONCLUSIONS: This is the first large international cohort of persons with chronic and episodic migraine studied using a web-based approach, a methodology well suited to the study of the burden of migraines.

Entities:  

Mesh:

Year:  2011        PMID: 21690175     DOI: 10.1177/0333102411410610

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  23 in total

1.  Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).

Authors:  L M Bloudek; M Stokes; D C Buse; T K Wilcox; R B Lipton; P J Goadsby; S F Varon; A M Blumenfeld; Z Katsarava; J Pascual; M Lanteri-Minet; P Cortelli; P Martelletti
Journal:  J Headache Pain       Date:  2012-05-29       Impact factor: 7.277

2.  Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling.

Authors:  Anthony J Hatswell; Fleur Chandler
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

Review 3.  Economic burden and costs of chronic migraine.

Authors:  Michel Lanteri-Minet
Journal:  Curr Pain Headache Rep       Date:  2014-01

Review 4.  Update on the Pharmacological Treatment of Chronic Migraine.

Authors:  Christina Sun-Edelstein; Alan M Rapoport
Journal:  Curr Pain Headache Rep       Date:  2016-01

Review 5.  A Systematic Review of the Economic and Humanistic Burden of Gout.

Authors:  Gemma E Shields; Stephen M Beard
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

6.  Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden.

Authors:  Ronan Mahon; Andrea Lang; Pamela Vo; Jasper Huels; Philip Cooney; Andriy Danyliv; Umakanth Vudumula; Sreelatha Vadapalle; Farooq Maniyar; Peter J Goadsby
Journal:  Pharmacoeconomics       Date:  2021-01-25       Impact factor: 4.981

7.  Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.

Authors:  Theodoros V Giannouchos; Dimos-Dimitrios Mitsikostas; Robert L Ohsfeldt; Athanassios Vozikis; Paraskevi Koufopoulou
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

8.  Understanding the burden of adult female acne.

Authors:  Emil A Tanghetti; Ariane K Kawata; Selena R Daniels; Karen Yeomans; Caroline T Burk; Valerie D Callender
Journal:  J Clin Aesthet Dermatol       Date:  2014-02

9.  Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne.

Authors:  Valerie D Callender; Andrew F Alexis; Selena R Daniels; Ariane K Kawata; Caroline T Burk; Teresa K Wilcox; Susan C Taylor
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

10.  Living with Burden of Migraine: The Analysis of "My Migraine Voice" Survey Results in Turkey.

Authors:  Arife Çimen Atalar; Manal Bozkurt; Zeynep Çalişkan; Pamela Vo; Mustafa Ertaş; Betül Baykan
Journal:  Noro Psikiyatr Ars       Date:  2019-11-11       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.